CFO
JAZZ icon

Callan Family Office’s Jazz Pharmaceuticals JAZZ Stock Holding History

Callan Family Office’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
7,722
+364
+5% +$79.7K 0.04% 416
2026
Q1 		$1.39M Buy
7,358
+983
+15% +$172K 0.03% 468
2025
Q4 		$1.08M Buy
6,375
+3,930
+161% +$603K 0.02% 525
2025
Q3 		$322K Sell
2,445
-3,388
-58% -$406K 0.01% 686
2025
Q2 		$619K Buy
+5,833
New +$634K 0.02% 526
2025
Q1 		– Sell
-2,165
Closed -$267K – 600
2024
Q4 		$267K Buy
+2,165
New +$255K 0.02% 519

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Callan Family Office's JAZZ Position: Q2 2026 in Review

Callan Family Office increased its Jazz Pharmaceuticals (JAZZ) stake by 4.9% in Q2 2026, buying an estimated $79.7K and bringing the position to 7,722 shares worth $1.86M. The position accounts for 0.04% of the portfolio, ranked #416.

Callan Family Office first reported a position in JAZZ in Q4 2024 and has held it in 6 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Callan Family Office held 7,722 shares of Jazz Pharmaceuticals worth $1.86M as of Q2 2026.
  • Callan Family Office bought 364 Jazz Pharmaceuticals shares in Q2 2026, an estimated $79.7K.
  • Jazz Pharmaceuticals made up 0.04% of Callan Family Office's portfolio in Q2 2026, its #416 holding.
  • Callan Family Office first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.